ClinicalTrials.gg
Not yet recruitingNCT07946926FAMAUpdated Nov 18, 2026

Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services

An observational study in Addiction, sponsored by King's College London. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by King's College London · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
84
Ages
18 Years and older
Sex
All
01

Study summary

Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.

Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.

Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.

02

Conditions studied

  • Addiction

Browse trials for

03

In context

Behavior, Addictive

521 studies on the registry are indexed under Behavior, Addictive; 124 are open to participants now.

This study's planned enrollment of 84 is below the median of 158 across 106 observational studies indexed under Behavior, Addictive.

Browse Behavior, Addictive studies →

Lead sponsor

King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.

Eligibility criteria

Phase one (staff) inclusion criteria:

  • Aged 18+ years
  • Currently working in a paid client facing role in an AOD treatment service

Phase one (people accessing AOD treatment) inclusion criteria:

  • Aged 18+ years
  • Currently receiving treatment from an AOD treatment service

Phase two (staff) inclusion criteria:

  • Aged 18+ years
  • Currently working as a keyworker or recover worker in an AOD treatment service

Phase two (people accessing AOD treatment) inclusion criteria:

  • Aged 18+ years
  • Currently receiving treatment from an AOD treatment service
  • On a participating staff member's caseload
  • Not attending MAGs.

Exclusion Criteria:

  • N/A
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
84 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Qualitative focus groups

    Qualitative focus groups

    Time frame: Focus groups will last approximately 90 minutes

  2. Acceptability of Intervention measure (AIM) adapted for FAMA

    Measures whether participants find FAMA to be acceptable

    Time frame: Maximum 10 weeks from enrolment in the study

  3. Feasibility of Intervention (FIM) adapted for FAMA

    Measures whether participants find FAMA to be feasible

    Time frame: Maximum 10 weeks from enrolment in the study

  4. Appropriateness Measure (IAM) adapted for FAMA

    Measures whether participants find FAMA to be appropriate

    Time frame: Maximum 10 weeks from enrolment in the study

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946926
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion